Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19 CAR-T Cell(University Hospital of Lille) in Relapsing acute myeloid leukemia: NCT06649227 Clinical Landscape Report 2026
16 October 2026
NCT06649227 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Dexamethasone Sodium Phosphate in Relapse multiple myeloma: NCT06645678 Clinical Landscape Report 2026
16 October 2026
NCT06645678 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JNJ-90189892 in Acute Myeloid Leukemia: NCT06651229 Clinical Landscape Report 2026
16 October 2026
NCT06651229 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revumenib in Acute Myeloid Leukemia: NCT06652438 Clinical Landscape Report 2026
16 October 2026
NCT06652438 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LCAR-AIO(Legend Biotech) in Systemic Lupus Erythematosus: NCT06653556 Clinical Landscape Report 2026
16 October 2026
NCT06653556 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Decitabine in Acute Myeloid Leukemia: NCT06651866 Clinical Landscape Report 2026
16 October 2026
NCT06651866 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RD-140 in Plasma Cell Leukemia: NCT06655519 Clinical Landscape Report 2026
16 October 2026
NCT06655519 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HC022 in Systemic Lupus Erythematosus: NCT06657703 Clinical Landscape Report 2026
16 October 2026
NCT06657703 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mesutoclax in Myeloid Tumor: NCT06656494 Clinical Landscape Report 2026
16 October 2026
NCT06656494 clinical landscape for Myeloid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cladribine in Refractory acute myeloid leukemia: NCT06660368 Clinical Landscape Report 2026
16 October 2026
NCT06660368 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Gemcitabine Hydrochloride/Docetaxel in Non-Muscle Invasive Bladder Neoplasms: NCT06663137 Clinical Landscape Report 2026
16 October 2026
NCT06663137 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Mycophenolate Mofetil in Multiple Myeloma: NCT06663046 Clinical Landscape Report 2026
16 October 2026
NCT06663046 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.